New PML risk-evaluation - AAN 2009

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

New PML risk-evaluation - AAN 2009

Postby Frank » Sun Jun 14, 2009 4:22 pm

After at least one year of therapy the risk of PML was found to be 2.4 in 10,000.]

Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.
Family Elder
Posts: 543
Joined: Wed Jan 03, 2007 4:00 pm
Location: Germany


Return to Tysabri (Antegren or Natalizumab)

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service